NCT02759666View on ClinicalTrials.gov

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

March 8, 2019

Study Completion Date

April 26, 2019

Conditions
NeoplasmSolid Tumors
Interventions
DRUG

SHR3162

SHR3162 capsule(s) is administered orally QD.

Trial Locations (3)

2170

Liverpool Hospital, Liverpool

2640

Border Medical Oncology, Albury

Unknown

Linear, Melbourne

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT02759666 - A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter